Payment overview · 2025
General Payments
$623.79
25 reported records · 8 companies
Healthcare provider profile · identity verified
Jaclyn Grzybowski
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TAMPA, FL · NPI 1790083806
Verified facts
What the public records show
CMS Open Payments records show Jaclyn Grzybowski received $623.79 in general payments during 2025 across 25 reported records.
Novartis Pharmaceuticals Corporation accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $252.74 | 40.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $222.23 | 35.6% | 8 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.67 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.84 | 6.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.05 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.79 | 3.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.64 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.83 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.79 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $252.74 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.82 | 6 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $38.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 189 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 57 |
| Losartan Potassium | Losartan Potassium | 123 | 43 |
| Lisinopril | Lisinopril | 120 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 48 |
| Metformin Hcl | Metformin Hcl | 105 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 33 |
| Gabapentin | Gabapentin | 59 | 22 |
| Omeprazole | Omeprazole | 54 | 20 |
| Ozempic | Semaglutide | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 26 |
| Simvastatin | Simvastatin | 45 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 16 |
| Carvedilol | Carvedilol | 36 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Meloxicam | Meloxicam | 27 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | 12 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.79 · 25 records | Novartis Pharmaceuticals Corporation | ABRYSVO, COMIRNATY, Kerendia, LEQVIO, NEXLETOL, ONPATTRO, PREVNAR 20, REPATHA, WAINUA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error